Skip to main content

Table 1 Baseline characterstics of participating diabetic kidney disease patients

From: Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

 

Microalbuminuria

Macroalbuminuria

TSF (n = 15)

Placebo (n = 15)

P Value

TSF (n = 15)

Placebo (n = 15)

P Value

Age (yr)

56.1 ± 12.5

51.8 ± 8.5

.382

55.5 ± 8.2

58.0 ± 10.8

.522

Male/Female

9/6

7/8

.384

6/9

5/10

.400

BMI (kg/m2)

26.1 ± 3.7

26.0 ± 3.9

.950

25.9 ± 3.0

27.3 ± 2.9

.271

Blood pressure

 Systolic (mmHg)

131.9 ± 7.8

128.3 ± 5.6

.259

130.1 ± 8.3

131.1 ± 9.3

.777

 Diastolic (mmHg)

81.6 ± 6.4

76.2 ± 10.1

.142

78.6 ± 7.4

82.0 ± 4.9

.231

Laboratory variables

 FBG (mmol/L)

6.7 ± 0.9

5.7 ± 1.0

.097

6.9 ± 1.5

6.8 ± 0.7

.752

 A1C (%)

6.7 ± 0.6

6.5 ± 0.6

.065

6.7 ± 1.0

6.5 ± 1.3

.579

 TG (mmol/L)

2.5 ± 1.6

2.2 ± 1.2

.617

2.7 ± 1.8

2.2 ± 1.0

.528

 TC (mmol/L)

5.2 ± 0.9

4.9 ± 1.6

.532

5.2 ± 0.9

5.6 ± 1.2

.545

 LDL (mmol/L)

3.0 ± 0.9

3.2 ± 1.4

.729

3.0 ± 1.2

3.8 ± 1.6

.293

 HDL (mmol/L)

1.3 ± 0.6

1.0 ± 0.3

.091

1.3 ± 0.4

1.5 ± 0.3

.182

 ALT (U/L)

26.2 ± 12.6

22.2 ± 9.1

.417

22.2 ± 8.7

22.9 ± 7.8

.835

 AST (U/L)

22.4 ± 7.8

17.2 ± 5.5

.102

20.3 ± 5.7

22.5 ± 8.5

.443

  1. Values expressed as mean ± SD
  2. Abbreviations: ALT alanine aminotransferase, A1C glycosylated hemoglobin, AST aspartate aminotransferase, BMI body mass index, FBG fasting blood glucose, HDL high density lipoprotein, LDL low density lipoprotein, TC total cholesterol, TG triglyceride